A multi-center, double-blind, randomized, parallel group, placebo-controlled 24-week study to investigate glycemic parameters of efficacy and safety/tolerability in patients with type 2 diabetes mellitus randomized to two dose levels of RO4998452, or placebo.
Latest Information Update: 04 Aug 2010
At a glance
- Drugs Tofogliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Roche
- 04 Aug 2010 New trial record